Christian Ott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christian Ott has a total of 415 co-authors. Here are the top co-authors by number of shared publications:
- Roland E. Schmieder
Universitätsklinikum Erlangen
7 shared publications - Tilmann Ditting
Med Dept 4 (FAU &PMU), Erlangen and Nuremberg, Germany
7 shared publications - Michael Uder
Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
6 shared publications Roland Schmieder
Med Dept 4 (FAU), Erlangen, Germany
6 shared publications- Axel Schmid
Friedrich-Alexander-University of Erlangen-Nuremberg, Institute of Radiology, University Hospital Erlangen, Erlangen, Germany
5 shared publications Roland Veelken
Med Dept 4 (FAU &PMU), Erlangen and Nuremberg, Germany
5 shared publications
Latest Publications
- 1 September 2018
- Published by Wolters Kluwer Health in Hypertension
- Vol. 72 (Suppl_1)
Abstract 082: Intrarenal Nacl Boli Cause Longlasting Inhibition of Renal Sympathetic Nerve Activity (RSNA)
Afferent renal nerve fibers from the kidney likely counterregulate salt sensitive blood pressure increases by decreasing renal sympathetic nerve activity. We recently reported on a long-lasting tonic sympatho-inhibition due to intrarenal afferent renal nerve stimulation eliciting a TRPV1 dependent neuro-humoral pathway. We wanted to test the hypothesis that sodium influences this afferent sympatho-depressory mechanism. Groups of anesthetized SD rats (n=8) were equipped with femoral catheters (blood pressure (BP) & heart rate (HR) recording, drug application), a renal arterial catheter for intrarenal administration (IRA) of high salt (10 % NaCl, 10 μl) or Capsaicin (CAP 3.3, 6.6, 10, 33*10-7 M, 10 μl) and a bipolar electrode for RSNA recordings; eventually an intravenous (iv) bolus of the NK1-receptor blocker RP67580 (10*10-3M, 15 μl) was given. Cultured dorsal root ganglion neurons (Th11-L2) of rats with renal afferents were investigated in current clamp mode to assess action potential generation or in voltage clamp mode to investigate inward currents during 10 sec superperfusion to 4.5 % NaCl or equiosmotic mannitol. solution Results are given in mean±SEM. IRA high salt and IRA CAP decreased RSNA from baseline 4.1±0.6 μV*sec to 2.2±0.8 μV*sec (10% NaCl, p<0.05) and 3.9±0.5 μV*sec to 0.9±0.2 μV*sec (CAP, p<0.01). Suppressed RSNA in high salt groups and CAP could be unmasked by systemic (i.v.) administration of the NK1-blocker (2.7±1.8 μV*sec to 5.8±2.2 μV*sec; p<0.05 (10% NaCl); 1.0±0.2 μV*sec to 6.1±1.5 μV*sec; p<0.01 (CAP)). Cultured renal neurons exhibited production of action potentials (3.5±0.8*, from baseline, p<0.05) and increased sustained inward currents from baseline during exposure to NaCl 4.5 % (-10708.8±3546.5 pA*, from baseline, p<0.05). No responses to equiosmolar mannitol. Increased intrarenal sodium concentrations might induce long-lasting sympatho-depression via a neuro-humoral TRPV1 dependent and tachykinin mediated afferent nerve pathway from the kidney. Impairment of this sympatho-depressory mechanism could be involved in salt sensitive hypertension.
- 1 September 2018
- Published by Wolters Kluwer Health in Hypertension
- Vol. 72 (Suppl_1)
Abstract 082: Intrarenal Nacl Boli Cause Longlasting Inhibition of Renal Sympathetic Nerve Activity (RSNA)
Afferent renal nerve fibers from the kidney likely counterregulate salt sensitive blood pressure increases by decreasing renal sympathetic nerve activity. We recently reported on a long-lasting tonic sympatho-inhibition due to intrarenal afferent renal nerve stimulation eliciting a TRPV1 dependent neuro-humoral pathway. We wanted to test the hypothesis that sodium influences this afferent sympatho-depressory mechanism. Groups of anesthetized SD rats (n=8) were equipped with femoral catheters (blood pressure (BP) & heart rate (HR) recording, drug application), a renal arterial catheter for intrarenal administration (IRA) of high salt (10 % NaCl, 10 μl) or Capsaicin (CAP 3.3, 6.6, 10, 33*10-7 M, 10 μl) and a bipolar electrode for RSNA recordings; eventually an intravenous (iv) bolus of the NK1-receptor blocker RP67580 (10*10-3M, 15 μl) was given. Cultured dorsal root ganglion neurons (Th11-L2) of rats with renal afferents were investigated in current clamp mode to assess action potential generation or in voltage clamp mode to investigate inward currents during 10 sec superperfusion to 4.5 % NaCl or equiosmotic mannitol. solution Results are given in mean±SEM. IRA high salt and IRA CAP decreased RSNA from baseline 4.1±0.6 μV*sec to 2.2±0.8 μV*sec (10% NaCl, p<0.05) and 3.9±0.5 μV*sec to 0.9±0.2 μV*sec (CAP, p<0.01). Suppressed RSNA in high salt groups and CAP could be unmasked by systemic (i.v.) administration of the NK1-blocker (2.7±1.8 μV*sec to 5.8±2.2 μV*sec; p<0.05 (10% NaCl); 1.0±0.2 μV*sec to 6.1±1.5 μV*sec; p<0.01 (CAP)). Cultured renal neurons exhibited production of action potentials (3.5±0.8*, from baseline, p<0.05) and increased sustained inward currents from baseline during exposure to NaCl 4.5 % (-10708.8±3546.5 pA*, from baseline, p<0.05). No responses to equiosmolar mannitol. Increased intrarenal sodium concentrations might induce long-lasting sympatho-depression via a neuro-humoral TRPV1 dependent and tachykinin mediated afferent nerve pathway from the kidney. Impairment of this sympatho-depressory mechanism could be involved in salt sensitive hypertension.
- Open Access
- 4 January 2018
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 17 (1) , 1-8
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
Background and aims: Sodium tissue content by23Na magnetic resonance imaging (Na-MRI) has been validated in experimental and human studies. SGLT-2 inhibition blocks the reabsorption of glucose and of sodium in the proximal tubular cells in a 1:1 fashion. We hypothesized that SGLT-2 inhibition in patients with type 2 diabetes characterized by sodium retention leads to decreased tissue sodium content due to its pharmacological action.Materials and methods: In a prospective double blind, placebo controlled, cross-over trial 59 patients (61 ± 7.6 years) with type 2 diabetes were randomized to either dapagliflozin 10 mg or placebo once daily for 6 weeks each. In addition to metabolic parameters and ambulatory blood pressure (BP) we analysed the sodium content in the skin and muscles of the lower leg by Na-MRI.Results: Compared to baseline 6 weeks treatment with the SGLT-2 inhibitor dapagliflozin decreased fasting (132 ± 28 vs. 114 ± 19 mg/dl, p < 0.001), postprandial blood glucose (178 ± 66 mg/dl vs. 153 ± 46 mg/dl, p < 0.001), body weight (87.6 vs. 86.6 kg, p < 0.001) and systolic (129 ± 12 vs. 126 ± 11 mmHg, p = 0.010), and diastolic (77.4 ± 9 vs. 75.6 ± 8 mmHg, p = 0.024), 24-h ambulatory BP. Tissue sodium content in the skin was reduced after 6 weeks treatment with dapagliflozin compared to baseline [24.1 ± 6.6 vs. 22.7 ± 6.4 A.U.(arbitrary unit) p = 0.013]. No significant reduction of tissue sodium content was observed in the muscle (M. triceps surae: 20.5 ± 3.5 vs. 20.4 ± 3.7 A.U. p = 0.801). No clear significant difference in tissue water content of muscle and skin was observed after 6 weeks of treatment with dapagliflozin, compared to baseline.Conclusion: SGLT-2 inhibition with dapagliflozin resulted in a significant decrease in tissue sodium content of the skin after 6 weeks. This observation point to a decrease of total sodium content in patients with type 2 diabetes prone to cardiovascular complications, that might be mitigated by SGLT-2 inhibition.Trial registrationThe study was registered athttp://www.clinicaltrials.gov(NCT02383238) retrospectively registered
- 4 January 2018
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 17 (1) , 1-8
Open AccessSGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
Background and aims: Sodium tissue content by23Na magnetic resonance imaging (Na-MRI) has been validated in experimental and human studies. SGLT-2 inhibition blocks the reabsorption of glucose and of sodium in the proximal tubular cells in a 1:1 fashion. We hypothesized that SGLT-2 inhibition in patients with type 2 diabetes characterized by sodium retention leads to decreased tissue sodium content due to its pharmacological action.Materials and methods: In a prospective double blind, placebo controlled, cross-over trial 59 patients (61 ± 7.6 years) with type 2 diabetes were randomized to either dapagliflozin 10 mg or placebo once daily for 6 weeks each. In addition to metabolic parameters and ambulatory blood pressure (BP) we analysed the sodium content in the skin and muscles of the lower leg by Na-MRI.Results: Compared to baseline 6 weeks treatment with the SGLT-2 inhibitor dapagliflozin decreased fasting (132 ± 28 vs. 114 ± 19 mg/dl, p < 0.001), postprandial blood glucose (178 ± 66 mg/dl vs. 153 ± 46 mg/dl, p < 0.001), body weight (87.6 vs. 86.6 kg, p < 0.001) and systolic (129 ± 12 vs. 126 ± 11 mmHg, p = 0.010), and diastolic (77.4 ± 9 vs. 75.6 ± 8 mmHg, p = 0.024), 24-h ambulatory BP. Tissue sodium content in the skin was reduced after 6 weeks treatment with dapagliflozin compared to baseline [24.1 ± 6.6 vs. 22.7 ± 6.4 A.U.(arbitrary unit) p = 0.013]. No significant reduction of tissue sodium content was observed in the muscle (M. triceps surae: 20.5 ± 3.5 vs. 20.4 ± 3.7 A.U. p = 0.801). No clear significant difference in tissue water content of muscle and skin was observed after 6 weeks of treatment with dapagliflozin, compared to baseline.Conclusion: SGLT-2 inhibition with dapagliflozin resulted in a significant decrease in tissue sodium content of the skin after 6 weeks. This observation point to a decrease of total sodium content in patients with type 2 diabetes prone to cardiovascular complications, that might be mitigated by SGLT-2 inhibition.Trial registrationThe study was registered athttp://www.clinicaltrials.gov(NCT02383238) retrospectively registered
- Open Access
- 23 February 2017
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 1-9
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Background: The sodium–glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascular structure and function have not yet been reported. Methods: This was a prospective, single-centre, placebo-controlled, double-blind, randomised crossover phase IIIb study conducted between March 2014 and February 2015. After a 4-week run-in/washout phase, patients (N = 59) received 6 weeks of either dapagliflozin 10 mg or placebo once daily. They then underwent a 1-week washout before crossing over to the other treatment. Changes in retinal capillary flow (RCF) and arteriole remodelling were evaluated using scanning laser Doppler flowmetry, while micro- and macrovascular parameters in the systemic circulation were assessed using pulse wave analysis. Results: Six weeks of dapagliflozin treatment resulted in improvements in diabetes control, including blood glucose and insulin resistance, and reduced office and 24-h ambulatory blood pressure values. RCF decreased from 324 AU at baseline to 308 AU after treatment with dapagliflozin (p = 0.028), while there was little difference after the placebo (318 AU; p = 0.334). Furthermore, the arteriole remodelling that was seen after the placebo phase was not evident after the dapagliflozin phase. Central systolic and diastolic blood pressure values were significantly lower after 6 weeks of dapagliflozin, by 3.0 and 2.2 mmHg, respectively (p = 0.035 and 0.020, respectively vs. baseline). Conclusions: Six weeks of dapagliflozin treatment resulted in numerous beneficial effects. In addition to achieving superior diabetes control and blood pressure, parameters associated with the early stages of vascular remodelling were also improved. Trial registrationhttp://www.clinicaltrials.gov (NCT02383238)
- 23 February 2017
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 16 (1) , 1-9
Open AccessA randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
Background: The sodium–glucose cotransporter 2 inhibitor, dapagliflozin, has been shown to improve diabetic control and reduce blood pressure in patients with type 2 diabetes mellitus. Its effects on micro- and macrovascular structure and function have not yet been reported. Methods: This was a prospective, single-centre, placebo-controlled, double-blind, randomised crossover phase IIIb study conducted between March 2014 and February 2015. After a 4-week run-in/washout phase, patients (N = 59) received 6 weeks of either dapagliflozin 10 mg or placebo once daily. They then underwent a 1-week washout before crossing over to the other treatment. Changes in retinal capillary flow (RCF) and arteriole remodelling were evaluated using scanning laser Doppler flowmetry, while micro- and macrovascular parameters in the systemic circulation were assessed using pulse wave analysis. Results: Six weeks of dapagliflozin treatment resulted in improvements in diabetes control, including blood glucose and insulin resistance, and reduced office and 24-h ambulatory blood pressure values. RCF decreased from 324 AU at baseline to 308 AU after treatment with dapagliflozin (p = 0.028), while there was little difference after the placebo (318 AU; p = 0.334). Furthermore, the arteriole remodelling that was seen after the placebo phase was not evident after the dapagliflozin phase. Central systolic and diastolic blood pressure values were significantly lower after 6 weeks of dapagliflozin, by 3.0 and 2.2 mmHg, respectively (p = 0.035 and 0.020, respectively vs. baseline). Conclusions: Six weeks of dapagliflozin treatment resulted in numerous beneficial effects. In addition to achieving superior diabetes control and blood pressure, parameters associated with the early stages of vascular remodelling were also improved. Trial registrationhttp://www.clinicaltrials.gov (NCT02383238)
- 1 December 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (12) , 2475-2479
The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence
Data on the blood pressure (BP)-lowering effect of renal denervation (RDN) in moderate treatment-resistant hypertension (TRH) are limited. Moreover, change of adherence to medication, as one potential confounder of BP response, has never been analyzed rigorously in this group of patients. We analyzed the effect of RDN on BP in patients with moderate TRH who were retrospectively found to be completely adherent to their antihypertensive medication. Our study cohort comprised 40 patients with moderate TRH [office BP ≥ 140/90 but <160/100 mmHg and 24-h ambulatory BP monitoring (ABPM) ≥130/80 mmHg] who underwent catheter-based RDN. Further major inclusion criterion was complete adherence to their medication (≥80% intake of their prescribed antihypertensive drugs) at baseline (assessed by retrospective toxicological analysis). Six months after RDN, office BP was reduced by −10/−6 mmHg (SBP: 149 ± 6 vs. 139 ± 15 mmHg; DBP: 81 ± 12 vs. 75 ± 10 mmHg; both P < 0.001) and 24-h ABPM by −7/−4 mmHg (SBP: 150 ± 14 vs. 143 ± 16 mmHg, P = 0.005; DBP: 82 ± 10 vs. 78 ± 9 mmHg, P = 0.009). Number of prescribed antihypertensive medication [6.0 (5.0–6.0) vs. 5.5 (5.0–6.0), P = 0.013] and adherence rate (95.2 ± 7.6 vs. 91.7 ± 13.9%, P = 0.065) was slightly reduced 6 months after RDN, both likely to underestimate the true BP reduction. Thus, our data indicate that even after given full respect to drug adherence as potential confounder of BP response after RDN, both office and 24-h ABPM were substantially reduced in patients with moderate TRH.
- 1 December 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (12) , 2475-2479
The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence
Data on the blood pressure (BP)-lowering effect of renal denervation (RDN) in moderate treatment-resistant hypertension (TRH) are limited. Moreover, change of adherence to medication, as one potential confounder of BP response, has never been analyzed rigorously in this group of patients. We analyzed the effect of RDN on BP in patients with moderate TRH who were retrospectively found to be completely adherent to their antihypertensive medication. Our study cohort comprised 40 patients with moderate TRH [office BP ≥ 140/90 but <160/100 mmHg and 24-h ambulatory BP monitoring (ABPM) ≥130/80 mmHg] who underwent catheter-based RDN. Further major inclusion criterion was complete adherence to their medication (≥80% intake of their prescribed antihypertensive drugs) at baseline (assessed by retrospective toxicological analysis). Six months after RDN, office BP was reduced by −10/−6 mmHg (SBP: 149 ± 6 vs. 139 ± 15 mmHg; DBP: 81 ± 12 vs. 75 ± 10 mmHg; both P < 0.001) and 24-h ABPM by −7/−4 mmHg (SBP: 150 ± 14 vs. 143 ± 16 mmHg, P = 0.005; DBP: 82 ± 10 vs. 78 ± 9 mmHg, P = 0.009). Number of prescribed antihypertensive medication [6.0 (5.0–6.0) vs. 5.5 (5.0–6.0), P = 0.013] and adherence rate (95.2 ± 7.6 vs. 91.7 ± 13.9%, P = 0.065) was slightly reduced 6 months after RDN, both likely to underestimate the true BP reduction. Thus, our data indicate that even after given full respect to drug adherence as potential confounder of BP response after RDN, both office and 24-h ABPM were substantially reduced in patients with moderate TRH.
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e251
OS 28-03 SECRETORY CAPACITY OF PANCREATIC BETA CELLS IS ENHANCED 6 MONTHS AFTER RENAL DENERVATION IN TREATMENT RESISTANT HYPERTENSIVE PATIENTS
Renal denervation (RDN) lowers blood pressure (BP) by interruption of sympathetic nerve activity. A high sympathetic tone increases not only BP but also decreases pancreatic beta cell insulin secretion. Hence, the objective of the study was to analyze whether RDN improves secretory capacity of beta cells.In 40 patients (7 diabetics, 19 prediabetics, 14 non diabetics) with treatment resistant hypertension (defined by office BP ≥ 140/90 mmHg and diagnosis confirmed with 24-h ambulatory BP ≥ 130/80 mmHg), insulin secretion was measured before and 6 months after RDN (Simplicity flex catheter, Medtronic) by glucagon test. At each time point blood was sampled prior to glucagon administration and 6 minutes after intravenous injection of 1 ml glucagon for measurement of C-peptide, insulin and proinsulin (by ELISA).In these 40 patients (mean age 58 ± 12 years, mean office BP 154 ± 22 mmHg / 89 ± 14 mmHg while on 5.2 ± 1.4 antihypertensive drugs) office systolic and diastolic BP was significantly reduced 6 months after RDN (both p < 0.01). Fasting plasma glucose and HbA1c level was significantly reduced 6 month after RDN (both p < 0.01). Six months after RDN, the increase of C-peptide concentration and insulin concentration after glucagon injection was significantly higher compared to before RDN (both p < 0.05).Thus, our data indicate an improved pancreatic beta cell function after RDN in patients with treatment resistant hypertension.
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e251
OS 28-03 SECRETORY CAPACITY OF PANCREATIC BETA CELLS IS ENHANCED 6 MONTHS AFTER RENAL DENERVATION IN TREATMENT RESISTANT HYPERTENSIVE PATIENTS
Renal denervation (RDN) lowers blood pressure (BP) by interruption of sympathetic nerve activity. A high sympathetic tone increases not only BP but also decreases pancreatic beta cell insulin secretion. Hence, the objective of the study was to analyze whether RDN improves secretory capacity of beta cells.In 40 patients (7 diabetics, 19 prediabetics, 14 non diabetics) with treatment resistant hypertension (defined by office BP ≥ 140/90 mmHg and diagnosis confirmed with 24-h ambulatory BP ≥ 130/80 mmHg), insulin secretion was measured before and 6 months after RDN (Simplicity flex catheter, Medtronic) by glucagon test. At each time point blood was sampled prior to glucagon administration and 6 minutes after intravenous injection of 1 ml glucagon for measurement of C-peptide, insulin and proinsulin (by ELISA).In these 40 patients (mean age 58 ± 12 years, mean office BP 154 ± 22 mmHg / 89 ± 14 mmHg while on 5.2 ± 1.4 antihypertensive drugs) office systolic and diastolic BP was significantly reduced 6 months after RDN (both p < 0.01). Fasting plasma glucose and HbA1c level was significantly reduced 6 month after RDN (both p < 0.01). Six months after RDN, the increase of C-peptide concentration and insulin concentration after glucagon injection was significantly higher compared to before RDN (both p < 0.05).Thus, our data indicate an improved pancreatic beta cell function after RDN in patients with treatment resistant hypertension.
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e253
OS 29-03 INCREASED NEUROKININ RELEASE FROM AFFERENT RENAL NERVES IS ACCOMPANIED BY DECREASED AFFERENT ELECTRIC ACTIVITY
Objective: Afferent renal nerves exhibit a dual function. They influence intrarenal immunological processes by release of neurokinins like CGRP and control central sympathetic outflow via afferent electrical activity. The former seems to be important in renal inflammation whereas the sympathetic modulation by afferent electrical activity is not fully understood in cardiovascular disease and hypertension. Hence, we hypothesized that augmented effects of CGRP in renal inflammation occur with increased afferent renal nerve activity. Design and Method: As inflammatory model, normotensive renal inflammation (RI) was induced by i.v. injection of 1.75 mg/kg BW OX-7 antibody to rats to avoid confounding blood pressure effects by choosing a hypertensive model in the first place. Animals were investigated neurophysiologically and pathomorphologically using standard techniques 6 days after RI induction. Results: Blood pressure (BP) was normal, hence confounding BP effects were unlikely. RI rats exhibited albuminuria (61 ± 6 μg/24 h), infiltration of macrophages in the interstitium (26 ± 4 cells/hp field) and glomeruli (3.7 ± 0.6 cells/glomerular X-section). Pretreatment with the CGRP antagonist rCGRP 8-37 (15 nmol/kg) significantly reduced proteinuria and macrophage infiltration suggesting increased activity of CGRP. In an in-vitro assay, renal RI tissue exhibited increased CGRP release (14 ± 3 pg/ml vs. controls 6.8 ± 2.8 pg/ml; p < 0.05, n = 8). RI tissue from renally denervated rats showed no CGRP. Afferent renal nerve activity (ARNA; spikes/sec) was unexpectedly lower in RI compared to controls (8.0 ± 1.8 vs. 27.4 ± 4.1 Hz, n = 6, p < 0.05). On the other hand, the burst-frequency renal sympathetic nerve activity (RSNA) in RI was significantly higher than in controls (14.7 ± 0.9 vs. 11.5 ± 0.9 bursts/sec; n = 6, p < 0.05). Conclusions: In contrast to our hypothesis increased release of neurogenic CGRP aggravating RI occurred with decreased ARNA. Increased RSNA pointed to a reduced tonic inhibition by ARNA. The latter mechanism might worsen sympathetic dysregulation and renal damage as in hypertension.
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e253
OS 29-03 INCREASED NEUROKININ RELEASE FROM AFFERENT RENAL NERVES IS ACCOMPANIED BY DECREASED AFFERENT ELECTRIC ACTIVITY
Objective: Afferent renal nerves exhibit a dual function. They influence intrarenal immunological processes by release of neurokinins like CGRP and control central sympathetic outflow via afferent electrical activity. The former seems to be important in renal inflammation whereas the sympathetic modulation by afferent electrical activity is not fully understood in cardiovascular disease and hypertension. Hence, we hypothesized that augmented effects of CGRP in renal inflammation occur with increased afferent renal nerve activity. Design and Method: As inflammatory model, normotensive renal inflammation (RI) was induced by i.v. injection of 1.75 mg/kg BW OX-7 antibody to rats to avoid confounding blood pressure effects by choosing a hypertensive model in the first place. Animals were investigated neurophysiologically and pathomorphologically using standard techniques 6 days after RI induction. Results: Blood pressure (BP) was normal, hence confounding BP effects were unlikely. RI rats exhibited albuminuria (61 ± 6 μg/24 h), infiltration of macrophages in the interstitium (26 ± 4 cells/hp field) and glomeruli (3.7 ± 0.6 cells/glomerular X-section). Pretreatment with the CGRP antagonist rCGRP 8-37 (15 nmol/kg) significantly reduced proteinuria and macrophage infiltration suggesting increased activity of CGRP. In an in-vitro assay, renal RI tissue exhibited increased CGRP release (14 ± 3 pg/ml vs. controls 6.8 ± 2.8 pg/ml; p < 0.05, n = 8). RI tissue from renally denervated rats showed no CGRP. Afferent renal nerve activity (ARNA; spikes/sec) was unexpectedly lower in RI compared to controls (8.0 ± 1.8 vs. 27.4 ± 4.1 Hz, n = 6, p < 0.05). On the other hand, the burst-frequency renal sympathetic nerve activity (RSNA) in RI was significantly higher than in controls (14.7 ± 0.9 vs. 11.5 ± 0.9 bursts/sec; n = 6, p < 0.05). Conclusions: In contrast to our hypothesis increased release of neurogenic CGRP aggravating RI occurred with decreased ARNA. Increased RSNA pointed to a reduced tonic inhibition by ARNA. The latter mechanism might worsen sympathetic dysregulation and renal damage as in hypertension.
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e271
MPS 11-09 Renal Afferent Peptidergic Neurons in the Control of the Autonomous Nervous System – What are Primary Stimuli?
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e271
MPS 11-09 Renal Afferent Peptidergic Neurons in the Control of the Autonomous Nervous System – What are Primary Stimuli?
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e488-e489
PS 17-53 RETINAL CAPILLARY RAREFACTION IN PATIENTS WITH UNTREATED MILD-MODERATE HYPERTENSION
Objective: Microvascular rarefaction influences peripheral vascular resistance, perfusion and metabolism by affecting blood pressure and flow pattern. In hypertension microvascular rarefaction has been described in experimental animal studies as well as in capillaroscopy of skin and biopsies of muscle tissue in patients. Retinal circulation mirrors cerebral microcirculation and allows non-invasive investigations. The aim of this study is to compare capillary rarefaction of retinal vessels in hypertensive versus normotensive subjects. Design and method: The study cohort consisted of 134 male and female patients with hypertension stage 1 or 2 and 55 male and female healthy people. All patients were non-smoker. Retinal vascular parameters were measured in perfusion image, non-invasively and in vivo by scanning laser Doppler flowmetry (Heidelberg Engineering, Germany). Capillary rarefaction was assessed by capillary area (CapA) (in pixel-number) and intercapillary distance (ICD) (in μm) (Figure 1). Additionally retinal capillary flow (RCF) was measured. Results: ICD was greater in the hypertensive group (23.1 ± 5.8 μm vs 20.1 ± 4.2 μm, p = 0.001) compared to healthy individuals. Hypertensive patients showed less CapA compared to healthy people (1556 ± 649 vs 1821 ± 652, p = 0.013). Accordingly, RCF was significantly lower in the hypertensive group compared to the healthy control group (291 ± 71 AU vs 314 ± 61 AU, p = 0.018). Our data indicate a lower level of retinal capillary density in hypertensive patients. Conclusions: Patients with hypertension stage 1 or 2 showed retinal capillary rarefaction in comparison to healthy normotensive subjects.
- 1 September 2016
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 34 (Supplement) , e488-e489
PS 17-53 RETINAL CAPILLARY RAREFACTION IN PATIENTS WITH UNTREATED MILD-MODERATE HYPERTENSION
Objective: Microvascular rarefaction influences peripheral vascular resistance, perfusion and metabolism by affecting blood pressure and flow pattern. In hypertension microvascular rarefaction has been described in experimental animal studies as well as in capillaroscopy of skin and biopsies of muscle tissue in patients. Retinal circulation mirrors cerebral microcirculation and allows non-invasive investigations. The aim of this study is to compare capillary rarefaction of retinal vessels in hypertensive versus normotensive subjects. Design and method: The study cohort consisted of 134 male and female patients with hypertension stage 1 or 2 and 55 male and female healthy people. All patients were non-smoker. Retinal vascular parameters were measured in perfusion image, non-invasively and in vivo by scanning laser Doppler flowmetry (Heidelberg Engineering, Germany). Capillary rarefaction was assessed by capillary area (CapA) (in pixel-number) and intercapillary distance (ICD) (in μm) (Figure 1). Additionally retinal capillary flow (RCF) was measured. Results: ICD was greater in the hypertensive group (23.1 ± 5.8 μm vs 20.1 ± 4.2 μm, p = 0.001) compared to healthy individuals. Hypertensive patients showed less CapA compared to healthy people (1556 ± 649 vs 1821 ± 652, p = 0.013). Accordingly, RCF was significantly lower in the hypertensive group compared to the healthy control group (291 ± 71 AU vs 314 ± 61 AU, p = 0.018). Our data indicate a lower level of retinal capillary density in hypertensive patients. Conclusions: Patients with hypertension stage 1 or 2 showed retinal capillary rarefaction in comparison to healthy normotensive subjects.
- 3 August 2016
- Published by Springer Nature
- p. 321-337
Alternative Methods for Renal Denervation
- 2 July 2015
- Published by Springer Nature in Current Hypertension Reports
- Vol. 17 (8)
Renal Denervation for Resistant Hypertension: Past, Present, and Future
Renal denervation (RDN) for treatment of resistant hypertension was introduced only 5 years ago. A clear pathophysiological role of renal sympathetic activity for the initiation and maintenance of hypertension and promising data showing a substantial and sustained blood pressure (BP) reduction after RDN has promoted the widespread use of the method at least in Europe. However, in a pivotal trial that included a sham-control group, no significant BP lowering effects was observed. Afterwards, it became clear that methodological issues and poor performance and execution of the intervention have hampered the results of Symplicity HTN-3 study, thereby limiting its validity profoundly. Now, in 2015, the renaissance of RDN has begun and new randomized prospective clinical trials have or will be started soon. In the meantime, it may be wise not to ignore all previous findings, as a rescue therapy for treatment resistant hypertension. A new science era emerged, with changes of the interventional approach and selection of patients potentially profiting most from RDN.
- 2 July 2015
- Published by Springer Nature in Current Hypertension Reports
- Vol. 17 (8)
Renal Denervation for Resistant Hypertension: Past, Present, and Future
Renal denervation (RDN) for treatment of resistant hypertension was introduced only 5 years ago. A clear pathophysiological role of renal sympathetic activity for the initiation and maintenance of hypertension and promising data showing a substantial and sustained blood pressure (BP) reduction after RDN has promoted the widespread use of the method at least in Europe. However, in a pivotal trial that included a sham-control group, no significant BP lowering effects was observed. Afterwards, it became clear that methodological issues and poor performance and execution of the intervention have hampered the results of Symplicity HTN-3 study, thereby limiting its validity profoundly. Now, in 2015, the renaissance of RDN has begun and new randomized prospective clinical trials have or will be started soon. In the meantime, it may be wise not to ignore all previous findings, as a rescue therapy for treatment resistant hypertension. A new science era emerged, with changes of the interventional approach and selection of patients potentially profiting most from RDN.